Business Standard

Sunday, January 12, 2025 | 12:40 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Hikal freezes at 5% upper circuit on development of Favipiravir API

Favipiravir is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.

Hikal frozen 5% upper circuit on successful development of Favipiravir API
Premium

The company said it is in discussion with potential partners to supply the API and its intermediates

SI Reporter Mumbai
Shares of Hikal were locked in the upper circuit band of 5 per cent at Rs 115 on the BSE on Friday after the company announced the successful development of Favipiravir active pharmaceutical ingredient (API) and its intermediates. The drug is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.

The trading volumes on the counter more than doubled with a combined around 280,000 shares changing hands on the counter on the NSE and BSE. There were combined pending buy orders for 120,000 shares at 12:17 pm.

Favipiravir is a generic version

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in